Dr. Merck to lead ProTECTIII study at Rhode Island Hospital

July 30, 2013

Dr. Lisa Merck will be lead investigator at Rhode Island Hospital for a national study examining whether IV progesterone is an effective treatment for moderate to severe acute traumatic brain injury (TBI).  The study, known as ProTECTIII (Progesterone for the Treatment of Traumatic Brain Injury) is an NIH-sponsored phase III clinical trial being conducted at 36 sites nationally.  

More information about the study is available at the ProTECTIII website as well as Rhode Island Hospital's press release.